Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

Jinfeng Zhang; Wenzhong Yan; Wenwen Duan; Kurt Wüthrich; Jianjun Cheng

doi:10.3390/ph13090237

Tumor Immunotherapy Using A_2A Adenosine Receptor Antagonists

Pharmaceuticals (Basel). 2020 Sep 8;13(9):237. doi: 10.3390/ph13090237.

Authors

Jinfeng Zhang^{1

2}, Wenzhong Yan¹, Wenwen Duan¹, Kurt Wüthrich^{1

3}, Jianjun Cheng¹

Affiliations

¹ iHuman Institute, ShanghaiTech University, Shanghai 201210, China.
² School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
³ Department of Integrated Structural and Computational Biology, Scripps Research, La Jolla, CA 92037, USA.

Abstract

The A_2A adenosine receptor (A_2AAR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A_2AAR have been focused on the use of A_2AAR antagonists for the treatment of Parkinson's disease. More recently, the A_2AAR has attracted additional attention for its roles in immuno-oncology, and a number of A_2AAR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A_2AAR antagonists for cancer immunotherapy. The therapeutic potential of representative A_2AAR antagonists is discussed based on both animal efficacy studies and clinical data.

Keywords: GPCR; Parkinson’s disease; cancer therapy; drug binding modes; immuno-oncology.

Publication types

Review